Catalyst Biosciences (NASDAQ:CBIO) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Catalyst Biosciences (NASDAQ:CBIO) from a hold rating to a buy rating in a research note released on Thursday, ValuEngine reports.

Separately, Zacks Investment Research upgraded Catalyst Biosciences from a sell rating to a hold rating in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Catalyst Biosciences currently has an average rating of Buy and an average price target of $23.75.

CBIO opened at $8.03 on Thursday. Catalyst Biosciences has a 1-year low of $6.20 and a 1-year high of $11.44. The firm has a fifty day simple moving average of $8.00. The company has a current ratio of 24.94, a quick ratio of 24.94 and a debt-to-equity ratio of 0.02. The company has a market cap of $97.28 million, a PE ratio of -3.00 and a beta of 2.10.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.01. Analysts predict that Catalyst Biosciences will post -4.88 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of CBIO. BlackRock Inc. increased its position in Catalyst Biosciences by 4.8% during the fourth quarter. BlackRock Inc. now owns 846,529 shares of the biopharmaceutical company’s stock worth $6,680,000 after acquiring an additional 39,088 shares during the period. Northern Trust Corp increased its position in Catalyst Biosciences by 12.3% during the fourth quarter. Northern Trust Corp now owns 152,246 shares of the biopharmaceutical company’s stock worth $1,202,000 after acquiring an additional 16,615 shares during the period. Dimensional Fund Advisors LP increased its position in Catalyst Biosciences by 25.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 508,232 shares of the biopharmaceutical company’s stock worth $4,010,000 after acquiring an additional 103,874 shares during the period. Geode Capital Management LLC increased its position in Catalyst Biosciences by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 144,175 shares of the biopharmaceutical company’s stock worth $1,137,000 after acquiring an additional 5,405 shares during the period. Finally, Bank of America Corp DE increased its position in Catalyst Biosciences by 1,127.7% during the fourth quarter. Bank of America Corp DE now owns 58,559 shares of the biopharmaceutical company’s stock worth $462,000 after acquiring an additional 53,789 shares during the period. Hedge funds and other institutional investors own 68.30% of the company’s stock.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Read More: Rule of 72

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.